The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine

Annals of Clinical Biochemistry

Volumn 47, Issue 1, 2010, Pages 17-28

  Blackwell, Scott ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE; ROSIGLITAZONE; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ATTENUATION; BIOCHEMISTRY; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMMUNE DEFICIENCY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID PEROXIDATION; LIVER DYSFUNCTION; MASS FRAGMENTOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; STABLE ANGINA PECTORIS; SYSTEMIC VASCULAR RESISTANCE;

AMIDOHYDROLASES; ANIMALS; ARGININE; BIOCHEMISTRY; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PROGNOSIS;

EID: 75149122890     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2009.009196     Document Type: Review

References (139)

1. G dimethyl-arginine, Nε-mono, di, and trimethyllysine, and glucosylgalactosyl-and galactosyldl-δ-hydroxylysine from human urine. J Biol Chem 1970;230:5751-8
2. Paik WK, Kim S. Protein methylase I. Purification and properties of the enzyme. J Biol Chem 1968;243:2108-14
3. Ghosh SK, Paik WK, Kim S. Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme. J Biol Chem 1988;263:19024-33
4. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005;10:S3-9
5. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105
6. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumuru K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003;42:985-90
7. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-9
8. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5
9. G-dimethylarginine in the rabbit. Biochem J 1976;154:179-84
10. G dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem 1989;264: 10205-9
11. Palm F, Onozato MI, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 2007;239:H3227-45
12. McAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-40
13. G-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007;101:627-35
14. Nijveldt RJ, Teerlink T, Siroen MPC, van Lambalgen AA, Rauwerda JA, van Leeuwen PAM. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22
15. Nijveldt RJ, van Leeuwen PAM, van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002;17:1999-2002
16. Richir MC, Bouwman RH, Teerlink T, et al. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. J Parent Ent Nutr 2008;32:613-22
17. Nijveldt RJ, Teerlink T, van der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30
18. Dayoub H, Acham V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence. Circulation 2003;108:3042-7
19. Dayoub H, Rodionov R, Lynch C, et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine- induced endothelial dysfunction in the cerebral circulation. Stroke 2008;39:180-4
20. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004;20(Suppl. B):7B-15B
21. Blackwell S, O'Reilly D St J, Talwar D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur J Clin Invest 2007;37:364-71
22. Murray-Rust J, Leiper JM, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylamino-hydrolases. Nat Struct Biol 2001;8:679-83
23. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5
24. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus. Role of asymmetric dimethylarginine and dimethylarginine dimethylamino-hydrolase. Circulation 2002;106:987-92
25. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001;104:2569-75
26. Zhang WZ, Venardos K, Chin-Dusting J, Kaye DM. Adverse effects of cigarette smoke on NO availability. Role of arginine metabolism and oxidative stress. Hypertension 2006;48:278-85
27. Sydow K, Münzel T. ADMA and oxidative stress. Atherosclerosis Suppl 2003;4:41-51
28. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 1988;333:664-6
29. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995;269:H1522-7
30. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001;14:1142-8
31. Kielsten JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-7
32. Kielstein JT, Simmel S, Bode-Böger SM, et al. Sub-pressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004;27:143-7
33. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005;10:S89-95
34. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007;282:879-87
35. + carrier hCAT-2B. Nitric Oxide 1997;1:65-73
36. Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006;17:1128-34
37. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocys(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557- 64
38. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7
39. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DEL. Relations between asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006;184:383-8
40. Maas R, Quitzau K, Schwedhelm E, et al. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. Atherosclerosis 2007;191:211-9
41. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Results from the AtheroGene study. Circ Res 2005;97:e53-9
42. Maas R, Schwedhelm E, Kahl L, et al. Simultaneous assessment of endothelial function, nitric oxide synthase activity. Niric oxide-mediated signalling, and oxidative stress in individuals with and without hypercholesterolemia. Clin Chem 2008;54:292-300
43. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61
44. Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008;49:303-11
45. Young JM, Strey CH, George PM. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Heart Failure 2008;10:463-6
46. Valkonen VP, Laakso J, Päivä H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 2003;4:19-22
47. Panichi V, Mantuano E, Paoletti S. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008;21:38-44
48. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003;166:279-84
49. Janatuinen T, Laakso J, Laaksonen R, et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003;8:185-9
50. Böger GI, Rudolph TK, Maas R, et al. Asymmetric dimethylarginine determines the improvement of endothelial-dependent vasodilation by simvastatin. Effect of combination with L-arginine. J Am Coll Cardiol 2007;49:2274-82
51. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35
52. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 2005;10:S35-43
53. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;106:987-92
54. Okyay K, Cengel A, Sahinarslan A, et al. Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coronary Artery Dis 2007;18:539-44
55. Anderson JL, Carlquist JF, Roberts WL, et al. Asymmetric dimethylarginine, cortisol/cortisone ratio and C-peptide: markers for diabetes and cardiovascular risk? Am Heart J 2007;153:67-73
56. Mittermayer F, Kautzky-Willer A, Winzer C, et al. Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med 2007;261:392-8
57. McLaughlin T, Stühlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006;91:1896-900
58. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovarian syndrome before and after metformin treatment. J Clin Endocrinol Met 2008;93:82-90
59. Abbasi F, Asagami T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3
60. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007;24:81-6
61. Asagami T, Abbasi F, Stülinger C, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002;51:843-6
62. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007;12:311-8
63. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. all-trans-retinoic acid increases nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003;92:226-33
64. Yasuda S, Miyazaki S, Kanda M, et al. Intensive treatment of risk factors in patients with type 2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine, an endogenous inhbitor of nitric oxide synthase. Eur Heart J 2006;27:1159-65
65. Jacobi J, Tsao P. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008;28:224-37
66. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2005;47:42-50
67. Wang D, Strandgaard S, Borresen ML, et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008;51:184-91
68. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modelling approach. J Am Soc Nephrol 2005;16:2449-55
69. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61
70. Zoccali C, Bendetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6
71. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine in haemodialysis patients. Kidney Int 2002;62:339-45
72. Zoccali C, Bode-Böger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358: 2113-7
73. Kielstein JT, Salpeter SR, Bode-Böger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006;21:2446-51
74. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8
75. Takiuchi S, Fuji H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004;17:802-8
76. Melikian N, Wheatcroft SB, Ogah OS, et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black African men. Hypertension 2007;49:873-7
77. Williams B, Poulter NR, Brown MJ, et al. The BHS Guidelines Working Party guidelines for management of hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertension 2004;18:139-85
78. Delles C, Schnieder MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590-3
79. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensin-converting enzyme inhibtion induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5
80. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001;65:775-8
81. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin- converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide availabillity and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-82
82. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitorin patients with type 2 diabetes mellitus. Circ J 2002;66:811-5
83. Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial fiunctions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25:324-6
84. Tomiyama H, Yamada J, Koji Y, Shiina K, Yoshida M, Yamashina A. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens 2007;20:1305-11
85. Jiang JL, Zhu HQ, Chen Z, Xu HY, Li YJ. Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level. Int J Cardiol 2005;101:153-5
86. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493.e1-8
87. Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006;27:824-31
88. Sahinarslan A, Cengel A, Biberoglu G, Hasanoglu A, Turkoglu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis 2006;17:605-9
89. Joyal D, Leya F, Al-Chekakie MO, et al. Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease. Coron Art Dis 2007;18:471-5
90. Furuki K, Adachi H, Enomoto M, et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six year prospective study using carotid ultrasonography. Hypertens Res 2008;31:1185-9
91. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8
92. Meinitzer A, Seelhorst U,Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen risk and cardiovascular health study). Clin Chem 2007;53:273-83
93. Zeller M, Korandji C, Guilland JC, et al. Impact of asymmetric dimethytlarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:954-60
94. Dückelmann C, Mittermayer F, Haider DG, et al. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007;27:2037- 42
95. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006;26:2536-40
96. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008;31:747-52
97. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-9
98. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HO. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9
99. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/Kooperative Gesundheitsforschung in der Region Augsburg Study and experimental data. Clin Chem 2007;53:693-701
100. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and non-fatal myocardial infarction and stroke in women. 24 year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008;28:961-7
101. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592-600
102. Bae SW, Stühlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005;95:729-33
103. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005;26:1846-51
104. O'Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethylarginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care 2006;10:139-45
105. Nijveldt RJ, Siroen MPC, Teerlink T, van Lambalgen AA, Rauwerda JA, van Leeuwen PAM. Gut and liver handling of asymmetric and symmetric dimethylarginines in the rat under basal conditions and during endotoxaemia. Liver Int 2004;24:510-8
106. Nijveldt RJ, Teerlink T, van Leeuwen PAM. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003;22:99-104
107. van den Berghe G,Wouters P,Weekers F, et al. Intensive insulin therapy in critically ill patients. N Eng J Med 2001;345:1359-67
108. Siroen MPC, van Leeuwen PAM, Nijveldt RJ, et al. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 2005;33:504-10
109. Eid HMA, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinaemia. Metab Clin Exper 2007;56:464-9
110. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. NEJM 2001;345:588-97
111. López A, Lorente JA, Steingrub J, et al. Multiple-center, randomised, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30
112. Leiper JM, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Nat Acad Sci 2002;99:13527-32
113. G-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995;269:C750-6
114. Blackwell S, O'Reilly D St J, Talwar D. HPLC analysis of asymmetric dimethylarginine (ADMA) and related arginine metabolites in human plasma using a novel non-endogenous internal standard. Clin Chim Acta 2009;401:14-9
115. Meinitzer A, Puchinger M, Winkelhofer-Roob BM, et al. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin Chim Acta 2007;384:141-8
116. G′-dimethyl-L-arginine in plasma by liquid chromatography as AccQ-FluorTM fluorescent derivatives. J Chrom B 2004;805:325-9
117. Zhang W, Kaye DM. Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Anal Biochem 2004;326:87-92
118. Marra M, Bonfilgi AR, Testa R, Testa I, Gambini A, Coppa G. High-performance liquid chromatography assay of asymmetric dimethylarginine, symmetric dimethylarginine and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal Biochem 2003;318:13-7
119. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303:131-7
120. Pettersson A, Uggla L, Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chrom B 1997;692:257-62
121. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chrom B 2007;851:221-9
122. Bishop MJ, Crow B, Norton D, Paliakov E, George J, Bralley JA. Direct analysis of underivatized asymmetric dimethylarginine (ADMA) and L-arginine from plasma using mixed-mode ion-exchange liquid chromatography-tandem mass spectrometry. J Chrom B 2007;859:164-9
123. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-93
124. Kircherr H, Kühn-Velten WN. HPLC-tandem mass spectrometric method for rapid quantification of dimethylarginines in human plasma. Clin Chem 2005;51:249-52
125. Martens-Lobenhoffer J, Bode-Böger SM. Simultaneous detection of arginine, asymmetric dimethylarginine, symmetric dimethylarginine and citrulline in human plasma and urine applying liquid chromatography-mass spectrometry with very straightforward sample preparation. J Chrom B 2003;798:231-9
126. G-dimethyl-Larginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chrom B 2004;809:59-65
127. Tsikas D, Schubert B, Gutzki FM, Sandmann J, Frölich JC. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri (N-pentafluoropropionyl) derivative. J Chrom B 2003;798:87-99
128. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-83
129. Široká R, Trefil L, Rajdl D, Racek J, Cibulka R. Asymmetric dimethylarginine - comparison of HPLC and ELISA methods. J Chrom B 2007;850:586-7
130. Valtonen P, Karppi J, Nyyssön K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chrom B 2005;828:97-102
131. Martens-Lobenhoffer J,Westphal S, Awiszus F, Bode-Böger SM, Luley C. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem 2005;51:2188-9
132. G-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005;35:622-6
133. Vallance P, Leiper J. Asymmetric dimethylarginine and kidney disease - marker or mediator? J Am Soc Nephrol 2005;16:2254-6
134. Fraser CG, Hyltoft Petersen P. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321-3
135. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005;43:1130-8
136. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chrom B 2007;851:21-9
137. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6
138. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chrom B 2007;851:42-50
139. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med 2004;42:758-64